Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells With Aberrant Akt Activity

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-04-0035
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Dual Inhibition of PI3K and mTOR Mitigates Compensatory AKT Activation and Improves Tamoxifen Response in Breast Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2013English

Vertical Inhibition of the PI3K/Akt/mTOR Pathway Is Synergistic in Breast Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2017English

TAZ Inhibition Restores Sensitivity of Cisplatin via AKT/mTOR Signaling in Lung Adenocarcinoma

Oncology Reports
MedicineCancer ResearchOncology
2017English

Serum Adenosine Deaminase Activity in Iraqi Patients With Breast Cancer on Tamoxifen Therapy

Gaziantep Medical Journal
2012English

Luminal Breast Cancer Cell Lines Overexpressing ZNF703 Are Resistant to Tamoxifen Through Activation of Akt/mTOR Signaling

PLoS ONE
Multidisciplinary
2013English

Inhibition of Constitutively Activated Phosphoinositide 3-Kinase/Akt Pathway Enhances Antitumor Activity of Chemotherapeutic Agents in Breast Cancer Susceptibility Gene 1-Defective Breast Cancer Cells

Molecular Carcinogenesis
Cancer ResearchMolecular Biology
2012English

Calmodulin Modulates Akt Activity in Human Breast Cancer Cell Lines

Breast Cancer Research and Treatment
Cancer ResearchOncology
2008English

IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2017English

Rottlerin Exerts Its Anti-Tumor Activity Through Inhibition of Skp2 in Breast Cancer Cells

Oncotarget
Oncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy